365 related articles for article (PubMed ID: 23727584)
21. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
22. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
[TBL] [Abstract][Full Text] [Related]
24. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.
O'Reilly J; Meyer B; Baker D; Herrmann R; Cannell P; Davies J
Leukemia; 1995 Apr; 9(4):624-7. PubMed ID: 7723395
[TBL] [Abstract][Full Text] [Related]
25. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
26. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
28. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; Moos M; Cremer FW
Br J Haematol; 2004 Sep; 126(5):665-74. PubMed ID: 15327517
[TBL] [Abstract][Full Text] [Related]
29. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
[TBL] [Abstract][Full Text] [Related]
30. Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.
Sata H; Shibayama H; Maeda I; Habuchi Y; Nakatani E; Fukushima K; Fujita J; Ezoe S; Tadokoro S; Maeda T; Mizuki M; Kosugi S; Nakagawa M; Ueda S; Iida M; Tokumine Y; Azenishi Y; Mitsui H; Oritani K; Kanakura Y
Exp Hematol; 2015 May; 43(5):374-381.e2. PubMed ID: 25591497
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
34. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
[TBL] [Abstract][Full Text] [Related]
35. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
[TBL] [Abstract][Full Text] [Related]
36. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.
Bader P; Hancock J; Kreyenberg H; Goulden NJ; Niethammer D; Oakhill A; Steward CG; Handgretinger R; Beck JF; Klingebiel T
Leukemia; 2002 Sep; 16(9):1668-72. PubMed ID: 12200679
[TBL] [Abstract][Full Text] [Related]
38. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
[TBL] [Abstract][Full Text] [Related]
39. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
[TBL] [Abstract][Full Text] [Related]
40. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
